Pulmonary arterial hypertension (PAH) is a rare and progressive disorder. Current treatment in the pediatric population includes phosphodiesterase 5 inhibitors (PDE-5i), endothelin receptor antagonists (ERA), and both inhaled and intravenous prostacyclin pathway agonists. As of December 22, 2015 the first oral prostacyclin pathway agonist, selexipag (Uptravi®), was FDA approved in the US. In this case series, we discuss our single-center experience using selexipag in a pediatric population, composed of both patients with idiopathic PAH, and patients with congenital heart disease and PAH.
Farber HW, Miller D, Poms AD et al (2015) Five-year outcomes of patients enrolled in the REVEAL registry. Chest 148:1043–1054CrossRefPubMedGoogle Scholar
Haworth SG, Hislop AA (2009) Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001–2006. Heart 95:312–317CrossRefPubMedGoogle Scholar
Kitterman N, Poms A, Miller DP et al (2012) Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY®. Mayo Clin Proc 87(9):825–834CrossRefPubMedPubMedCentralGoogle Scholar
Kallen AJ, Lederman E, Balaji A et al (2008) Bloodstream infections in patients given treatment with intravenous prostanoids. Infect Control Hosp Epidemiol 29(4):342–349CrossRefPubMedGoogle Scholar
Marr CR, McSweeney JE, Mullen MP, Kulik TJ (2015) Central venous line complications with chronic ambulatory infusion of prostacyclin analogues in pediatric patients with pulmonary arterial hypertension. Pulm Circ 5(2):322–326CrossRefPubMedPubMedCentralGoogle Scholar
Drogalis-Kim D, Jefferies J, Wilmot I, Alejos J (2016) Right sided heart failure and pulmonary hypertension: new insights into disease mechanisms and treatment modalities. Prog Pediatr Cardiol 43:71–80CrossRefGoogle Scholar